Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations
- 1 September 1994
- journal article
- review article
- Published by SAGE Publications in Angiology
- Vol. 45 (9) , 755-761
- https://doi.org/10.1177/000331979404500902
Abstract
Part I of this review discussed pharmacotherapy of primary pulmonary hypertension (PHT). Part II describes the value and limitations of oxygen and vasodilator therapy of secondary PHT, focusing on patients with PHT associated with selected connective tissue disease and chronic nonthrombotic hypoxic lung disease.Keywords
This publication has 21 references indexed in Scilit:
- Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue diseaseThe American Journal of Cardiology, 1991
- Hypoxic Pulmonary Vasoconstriction in Systemic Sclerosis and Primary Pulmonary Hypertension*Chest, 1991
- Nifedipine and Prazosin in the Management of Pulmonary Hypertension in CREST SyndromeChest, 1990
- The pulmonary pathologic manifestations of the CREST syndromeHuman Pathology, 1990
- Sustained benefit of verapamil in pulmonary hypertension with progressive systemic sclerosisAmerican Heart Journal, 1985
- Cardiovascular manifestations of mixed connective tissue disease in adults.Circulation, 1983
- Vascular reactivity and pulmonary hypertension in systemic sclerosisArthritis & Rheumatism, 1983
- Intérêt du captopril dans le traitement d'une hypertension artérielle systémique et pulmonaire avec activité rénine plasmatique augmentée au cours d'une sclérodermieLa Revue de Médecine Interne, 1983
- Nifedipine Treatment for Pulmonary Hypertension in a Patient with Systemic SclerosisArthritis & Rheumatism, 1983
- Pulmonary vascular changes in sclerodermaThe American Journal of Medicine, 1978